Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data
Christine Fischer, Rainer Hofmann, Axel Hegele Department of Urology and Pediatric Urology, University Medical Center, Marburg, GermanyCorrespondence: Christine FischerDepartment of Urology and Pediatric Urology, University Medical Center, Baldingerstraße, Marburg, GermanyEmail Christine.a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-06-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/chemotherapy-of-locally-advanced-or-metastatic-urothelial-cell-carcino-peer-reviewed-article-CMAR |
| _version_ | 1819229740988366848 |
|---|---|
| author | Fischer C Hofmann R Hegele A |
| author_facet | Fischer C Hofmann R Hegele A |
| author_sort | Fischer C |
| collection | DOAJ |
| description | Christine Fischer, Rainer Hofmann, Axel Hegele Department of Urology and Pediatric Urology, University Medical Center, Marburg, GermanyCorrespondence: Christine FischerDepartment of Urology and Pediatric Urology, University Medical Center, Baldingerstraße, Marburg, GermanyEmail Christine.a.m.fischer@gmail.comBackground/Aim: Up to 30% of all patients will present with an advanced or a metastatic stage (mUCC) at the moment of the initial diagnosis of urothelial cell carcinoma of the bladder (UCC). We investigated the numbers, the efficacy and toxicity of different chemotherapies for mUCC in daily practice and “real-life” conditions and evaluated them substance-specifically.Patients and Methods: All patients with a mUCC, who were treated between January 1, 2006 and October 31, 2016 at the Department of Urology and Pediatric Urology at University Hospital Marburg (Germany), were retrospectively analyzed. We set the focus on demographic and tumor-specific data as well as on effectiveness, therapy sequences, and drug tolerance.Results: Forty-one patients were identified. Of the 41 patients, 85.4% of the patients in first-line therapy received gemcitabine/cisplatin. A large proportion of 85.4% received a second-line therapy and 40% a third-line therapy due to progress or relapse. Median overall survival (mOS) was 18 months including all patients and increased up to 29.5 months in the cases of three therapy lines.Conclusion: Our data reveal that chemotherapy of mUCC is effective and side effects are manageable in daily clinical practice.Keywords: urothelial carcinoma, metastatic urothelial carcinoma, bladder cancer |
| first_indexed | 2024-12-23T11:17:59Z |
| format | Article |
| id | doaj.art-1b18dfddf1a740b192e7e88485d5808c |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-23T11:17:59Z |
| publishDate | 2020-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-1b18dfddf1a740b192e7e88485d5808c2022-12-21T17:49:08ZengDove Medical PressCancer Management and Research1179-13222020-06-01Volume 125077508454847Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life DataFischer CHofmann RHegele AChristine Fischer, Rainer Hofmann, Axel Hegele Department of Urology and Pediatric Urology, University Medical Center, Marburg, GermanyCorrespondence: Christine FischerDepartment of Urology and Pediatric Urology, University Medical Center, Baldingerstraße, Marburg, GermanyEmail Christine.a.m.fischer@gmail.comBackground/Aim: Up to 30% of all patients will present with an advanced or a metastatic stage (mUCC) at the moment of the initial diagnosis of urothelial cell carcinoma of the bladder (UCC). We investigated the numbers, the efficacy and toxicity of different chemotherapies for mUCC in daily practice and “real-life” conditions and evaluated them substance-specifically.Patients and Methods: All patients with a mUCC, who were treated between January 1, 2006 and October 31, 2016 at the Department of Urology and Pediatric Urology at University Hospital Marburg (Germany), were retrospectively analyzed. We set the focus on demographic and tumor-specific data as well as on effectiveness, therapy sequences, and drug tolerance.Results: Forty-one patients were identified. Of the 41 patients, 85.4% of the patients in first-line therapy received gemcitabine/cisplatin. A large proportion of 85.4% received a second-line therapy and 40% a third-line therapy due to progress or relapse. Median overall survival (mOS) was 18 months including all patients and increased up to 29.5 months in the cases of three therapy lines.Conclusion: Our data reveal that chemotherapy of mUCC is effective and side effects are manageable in daily clinical practice.Keywords: urothelial carcinoma, metastatic urothelial carcinoma, bladder cancerhttps://www.dovepress.com/chemotherapy-of-locally-advanced-or-metastatic-urothelial-cell-carcino-peer-reviewed-article-CMARurothelial carcinomametastatic urothelial carcinomabladder cancer |
| spellingShingle | Fischer C Hofmann R Hegele A Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data Cancer Management and Research urothelial carcinoma metastatic urothelial carcinoma bladder cancer |
| title | Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data |
| title_full | Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data |
| title_fullStr | Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data |
| title_full_unstemmed | Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data |
| title_short | Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data |
| title_sort | chemotherapy of locally advanced or metastatic urothelial cell carcinoma monocentric real life data |
| topic | urothelial carcinoma metastatic urothelial carcinoma bladder cancer |
| url | https://www.dovepress.com/chemotherapy-of-locally-advanced-or-metastatic-urothelial-cell-carcino-peer-reviewed-article-CMAR |
| work_keys_str_mv | AT fischerc chemotherapyoflocallyadvancedormetastaticurothelialcellcarcinomamonocentricreallifedata AT hofmannr chemotherapyoflocallyadvancedormetastaticurothelialcellcarcinomamonocentricreallifedata AT hegelea chemotherapyoflocallyadvancedormetastaticurothelialcellcarcinomamonocentricreallifedata |